32results about How to "Lower viral load" patented technology

The invention discloses an anti-AIDS virus bullatacin patch for external use, which comprises a backing layer, a drug reservoir and an anti-sticking layer; a cotton medicinal non-woven fabrics with good permeability is used as the backing layer, a polymeric gel (an acrylate pressure-sensitive gel) as an adhesive; the patch comprises the prepared liquid of bullatacin, and a silicone-oil anti-sticking polyester film is functioned as an anti-sticking layer. The patch for external use has the advantages that not only the disadvantage of serious harmful and side effects of the existing oral or intravenous antitumor drug are solved, but also the disadvantage of heavy skin irritation and a certain extend of toxicity of traditional patches for external use are overcome, and the economic cost is reduced.

The invention discloses a drug delivery system for external use containing the effective composition of bullatacin locality drug; the effective composition containing the bullatacin locality drug is dissolved in a mixed liquid of absolute alcohol and propylene glycol and fully stirred and mixed, and then prepared into the drug delivery system for external use; the drug delivery system comprises apatch, an aerosol or a film agent. Adoptions of the natural substance bullatacin extracted from cherimoya and an external using manner of the invention overcomes the shortcoming that the antitumor drugs and anti-AIDS drug have to be orally used or intravenously medicated, and the drug delivery system can ensure the drug to be absorbed through the skin, thus slowly releasing the drug and reducing the delivery dosage of the drug and the economic cost for the treatment.

The present invention provides a compound of general formula I: and pharmaceutically acceptable salts and esters thereof. The provided compounds, compositions and methods are useful in the treatment of viral infections, particularly hepatitis C infections.

The invention discloses a high-efficiency breeding method for Lanzhou lily seedlings. The Lanzhou lily seedlings are used as explants, and the seedlings are subjected to the steps of seed collection, sterilization, germination, at least one propagation culture, strong seedling culture and bulb expansion culture. , to prepare lily seedlings. The beneficial effects of the invention are as follows: the invention uses seed germination instead of scale cuttings to produce seedlings, blocks the intergenerational spread and accumulation of viruses caused by scale cuttings, and significantly reduces the viral load of lily seedlings compared with the prior art , improve the heterogeneity of the seedling population, and effectively solve the defects of virus accumulation and narrow genetic background caused by asexual reproduction in Lanzhou lily seedling propagation. The breeding method can be used for the preservation of Lanzhou lily germplasm resources and the factory breeding of seedlings, which is beneficial to the breeding of new Lanzhou lily varieties, the rapid popularization of excellent varieties, the preservation and innovation of germplasm resources, and the improvement of the yield and quality of Lanzhou lily. .

The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.

The invention relates to the field of medicines and discloses an anti-A(H1N1) flu pharmaceutical composition and application thereof. The pharmaceutical composition comprises marine organisms and a traditional Chinese medicine composition. The efficient and safe pharmaceutical composition prepared from seven natural medicines has an anti-A(H1N1) flu effect, is good in curative effect, has no toxic or side effect and no drug dependence for human bodies, and is superior to the conventional drug preparation product; therefore, the pharmaceutical composition can be widely applied in preparation of an anti-A(H1N1) flu drug.